During the past two decades, tremendous progress has been made in the dendrimer-based delivery of therapeutic molecules including, for instance, small molecules, macromolecules, and genes. This review deals with recent successes in the development of promising biocompatible phosphorus dendrimers, a specific type of dendrimer, to deliver genes to treat cancers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402398 | PMC |
| http://dx.doi.org/10.37349/etat.2022.00071 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bioactive phosphorus dendrimers deliver protein/drug to tackle osteoarthritis via cooperative macrophage reprogramming.
Biomaterials
May 2025
State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering, Donghua University, Shanghai, 201620, China. Electronic address:
Article Synopsis
- - The study focuses on reprogramming synovial macrophages and creating an immune environment that supports bone and cartilage growth to address osteoarthritis (OA) effectively.
- - Researchers developed a nanosystem using bioactive phosphorus dendrimers loaded with catalase (CAT) and quercetin (Que), which helps shift macrophages to a beneficial anti-inflammatory state and supports cell health.
- - When tested on an OA mouse model, this system reduced cartilage damage, bone erosion, and inflammation, and it also showed potential in human-derived cells by promoting similar positive changes in macrophages from OA patients.
Development of TiF4-Dendrimer complex gel as an anti-demineralization agent for dentin: An in vitro study.
Dent Mater
December 2024
Dental Research Center, Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran; Restorative Dentistry Department, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
Objective: The anti-caries effects of titanium tetrafluoride (TiF4) are well-documented, but its low pH challenges clinical application. This study evaluated PEG-citrate dendrimer as a carrier to enhance TiF4 stability and efficacy.
Methods: PEG-citrate dendrimer and TiF4-dendrimer gel were synthesized, and their structures confirmed using Fourier Transform Infrared Spectroscopy (FTIR), Hydrogen Nuclear Magnetic Resonance (1H NMR), and Liquid Chromatography-Mass Spectrometry (LC-MS).
Dendrimers-Novel Therapeutic Approaches for Alzheimer's Disease.
Biomedicines
August 2024
Clinic of Psychiatry, Department of Psychiatry, Medical Department, Wrocław Medical University, 50-367 Wrocław, Poland.
Dendrimers are covalently bonded globular nanostructures that may be used in the treatment of Alzheimer's disease (AD). Nowadays, AD therapies are focused on improving cognitive functioning and not causal treatment. However, this may change with the use of dendrimers, which are being investigated as a drug-delivery system or as a drug per se.
View Article and Find Full Text PDFPhosphorus Dendrimers Co-deliver Fibronectin and Edaravone for Combined Ischemic Stroke Treatment via Cooperative Modulation of Microglia/Neurons and Vascular Regeneration.
Adv Healthc Mater
November 2024
State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering, Donghua University, Shanghai, 201620, P. R. China.
The development of new multi-target combination treatment strategies to tackle ischemic stroke (IS) remains to be challenging. Herein, a proof-of-concept demonstration of an advanced nanomedicine formulation composed of macrophage membrane (MM)-camouflaged phosphorous dendrimer (termed as AK137)/fibronectin (FN) nanocomplexes (NCs) loaded with antioxidant edaravone (EDV) to modulate both microglia and neurons for effective IS therapy is showcased. The created MM@AK137-FN/EDV (M@A-F/E) NCs with a mean size of 260 nm possess good colloidal stability, sustained EDV release kinetics, and desired cytocompatibility.
View Article and Find Full Text PDFBrain delivery of fibronectin through bioactive phosphorous dendrimers for Parkinson's disease treatment via cooperative modulation of microglia.
Bioact Mater
August 2024
State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering, Donghua University, Shanghai, 201620, PR China.
Effective treatment of Parkinson's disease (PD), a prevalent central neurodegenerative disorder particularly affecting the elderly population, still remains a huge challenge. We present here a novel nanomedicine formulation based on bioactive hydroxyl-terminated phosphorous dendrimers (termed as AK123) complexed with fibronectin (FN) with anti-inflammatory and antioxidative activities. The created optimized AK123/FN nanocomplexes (NCs) with a size of 223 nm display good colloidal stability in aqueous solution and can be specifically taken up by microglia through FN-mediated targeting.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!